Effects of Proton Pump Inhibitors on Kidney Transplant Recipients
Study Details
Study Description
Brief Summary
Use of proton pump inhibitors (PPIs) is quite common among renal transplant recipients and reduced kidney functions and hypomagnesemia with the use of PPIs have been reported. In this study, investigation of the effects of PPI use on the outcome of kidney transplant recipients is aimed.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Use of proton pump inhibitors (PPIs) is frequent among renal transplant recipients due to the common use of glucocorticoids in immunosuppresive regimens after transplantation. Reduced kidney functions and hypomagnesemia with the use of PPIs have been reported in various patient populations. However, few studies examined the effects of PPIs on kidney transplant recipients. Therefore, the aim of this study is to investigate the effects of PPI and/or histamine H2 receptor antagonist use on serum magnesium levels, allograft functions and survival in kidney transplant recipients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Only PPI Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists. |
|
| Only H2RA Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors. |
|
| PPI and H2RA Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists. |
|
| No Acid Suppressive Treatment Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists. |
Outcome Measures
Primary Outcome Measures
- Graft survival [5-10 years]
Secondary Outcome Measures
- Graft rejection [5-10 years]
Other Outcome Measures
- Serum magnesium levels [5-10 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists (Only PPI).
-
Kidney transplant recipients who used histamine H2 receptor antagonists and did not use proton pump inhibitors (Only H2RA).
-
Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists (PPI and H2RA).
-
Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists (No Acid Suppressive Treatment).
Exclusion Criteria:
- Patients who are unwilling or unable to consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine | İstanbul | Turkey | 34093 |
Sponsors and Collaborators
- Istanbul University
Investigators
- Principal Investigator: Yasar Caliskan, MD, Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
- Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016 Feb;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193.
- van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med. 2014 Feb;72(2):86-90.
- 332